|
|
|
Volumn 23, Issue 4, 2002, Pages 152-156
|
|
Cancer care Ontario's new drug funding program: Controlled introduction of expensive anticancer drugs
|
|
Author keywords
Equitable access; Funding policy; New Drug Funding Program
|
|
Indexed keywords
ANTHRACYCLINE;
ANTINEOPLASTIC AGENT;
CLODRONIC ACID;
DOCETAXEL;
EPIRUBICIN;
GEMCITABINE;
INTERFERON;
IRINOTECAN;
NAVELBINE;
PACLITAXEL;
PAMIDRONIC ACID;
RALTITREXED;
RITUXIMAB;
TOPOTECAN;
TRASTUZUMAB;
BREAST METASTASIS;
CANADA;
CANCER CENTER;
CANCER CHEMOTHERAPY;
COLORECTAL CANCER;
COMMUNITY HOSPITAL;
DECISION MAKING;
DRUG COST;
DRUG INDICATION;
ECONOMIC EVALUATION;
FINANCIAL MANAGEMENT;
HEALTH CARE ACCESS;
HEALTH CARE DELIVERY;
HEALTH CARE POLICY;
HEALTH PROGRAM;
KAPOSI SARCOMA;
LUNG NON SMALL CELL CANCER;
MELANOMA;
NONHODGKIN LYMPHOMA;
OVARY CANCER;
PANCREAS CANCER;
PRACTICE GUIDELINE;
REVIEW;
ANTINEOPLASTIC AGENTS;
DRUG COSTS;
DRUG THERAPY;
HEALTH SERVICES ACCESSIBILITY;
HUMANS;
NEOPLASMS;
ONTARIO;
PACLITAXEL;
PHARMACEUTICAL SERVICES;
PROGRAM DEVELOPMENT;
REGIONAL MEDICAL PROGRAMS;
STATE GOVERNMENT;
|
|
EID: 0036766438
PISSN: 02288699
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (10)
|
|
References (6)
|
